4-phenoxy quinoline compound containing dihydropicolinamide and dihydropyridazinamide and application of 4-phenoxy quinoline compound
By designing and synthesizing 4-phenoxyquinoline compounds containing dihydropyridine amide and dihydropyridazinamide, the shortcomings of existing c-Met kinase inhibitors in clinical practice have been overcome, achieving effective inhibition of c-Met kinase and anti-cancer activity, especially therapeutic effects on gastric cancer and breast cancer.
Patent Information
- Application Number
- CN202610276668.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-09
- Publication Date
- 2026-05-29
AI Technical Summary
Existing c-Met kinase inhibitors have poor efficacy in clinical treatment, unsatisfactory pharmacokinetic parameters, low oral bioavailability, and significant toxic side effects. There is a lack of novel inhibitors that are structurally sound, safe, and effective.
A series of 4-phenoxyquinoline compounds containing dihydropyridine amide and dihydropyridazinamide were designed and synthesized. By optimizing the molecular structure to improve the inhibitory activity against c-Met kinase, these compounds can be used to prepare drugs for the treatment and prevention of cancer.
These compounds significantly inhibit c-Met kinase activity and exhibit remarkable antitumor activity, particularly in vitro against gastric and breast cancer cells, making them suitable for the preparation of drugs for the treatment and prevention of cancer.